What is the market valuation of transthyretin amyloidosis treatment?

The market size of transthyretin amyloidosis treatment in 2027 is calculated to be USD 12.56 Billion.

How is the transthyretin amyloidosis treatment industry size expected to evolve during the forecast period?

Transthyretin Amyloidosis Treatment Market size was valued at USD 11.74 Billion in 2026 and is projected to grow at 8.27% CAGR from 2027 to 2036, crossing USD 25.99 Billion by 2036.

How is earlier ATTR diagnosis influencing treatment market expansion?

Improved clinical awareness, expanded screening, and advanced non-invasive diagnostics are enabling earlier identification of eligible patients. Timely diagnosis supports earlier therapeutic intervention and more appropriate disease management throughout the patient care pathway.

Why are gene-silencing therapies becoming strategically important in transthyretin amyloidosis treatment?

Gene-silencing technologies target the underlying disease mechanism by reducing abnormal protein production. These advances are expanding treatment options, strengthening precision medicine approaches, and supporting improved long-term disease management for patients with transthyretin amyloidosis.

Why does hereditary transthyretin amyloidosis lead the disease type segment?

Hereditary transthyretin amyloidosis accounted for 59.23% of the market share in 2026, supported by increased genetic testing, stronger disease awareness, earlier diagnosis, and wider availability of targeted treatment options.

What is driving the rapid growth of online pharmacies in the transthyretin amyloidosis treatment market?

Online pharmacies are expanding quickly as digital healthcare, telehealth, home delivery services, and prescription fulfillment platforms improve medication accessibility and patient support for long-term treatment management.

Why does North America lead the transthyretin amyloidosis treatment market?

North America held 40.61% in 2026, supported by advanced healthcare infrastructure, specialized rare-disease networks, greater disease awareness, and access to targeted treatments.

How is Europe driving growth in transthyretin amyloidosis treatment?

Europe is the fastest-growing region, supported by improving diagnosis, stronger referral pathways, expanding specialized services, and greater access to innovative therapies.

Which companies dominate the transthyretin amyloidosis treatment landscape?

Prominent players in the transthyretin amyloidosis treatment market include Pfizer Inc. (United States), Alnylam Pharmaceuticals, Inc. (United States), Ionis Pharmaceuticals, Inc. (United States), AstraZeneca plc (United Kingdom), BridgeBio Pharma, Inc. (United States), Prothena Corporation plc (United States), Intellia Therapeutics, Inc. (United States), Neurimmune AG (Switzerland), Akcea Therapeutics (United States), Bristol Myers Squibb Company (United States)